The advent of biosimilar drugs has been a great advantage for patients whose diseases are treated with biological drugs from the very beginning. Having more and more alternatives means a great change in the course of the disease for many people. But it is still necessary to influence training and information on these drugs and that it reaches all patients and professionals. Joaquín Rodrigo, general director of Sandoz for Spain and Portugal and president of BioSim, reviews the pending challenges in this interview.

READ MORE